Discovery of Novel Dual Bruton’s Tyrosine Kinase (BTK) and Janus Kinase 3 (JAK3) Inhibitors as A Promising Strategy for Rheumatoid Arthritis

[1]  Sohita Dhillon.  Orelabrutinib: First Approval , 2021, Drugs.

[2]  P. Sève,et al.  State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis , 2020, Expert opinion on pharmacotherapy.

[3]  E. Peeva,et al.  Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate , 2020, Arthritis & rheumatology.

[4]  Sohita Dhillon.  Tirabrutinib: First Approval , 2020, Drugs.

[5]  Yahiya Y. Syed.  Zanubrutinib: First Approval , 2020, Drugs.

[6]  Michael L. Wang,et al.  Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma , 2019, Leukemia.

[7]  Ling-Jun Ho,et al.  Useful message in choosing optimal biological agents for patients with autoimmune arthritis. , 2019, Biochemical pharmacology.

[8]  H. Thu,et al.  Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[9]  R. Everley,et al.  PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. , 2019, ACS chemical biology.

[10]  Yifan Feng,et al.  Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018) , 2019, Expert opinion on therapeutic patents.

[11]  Sung,et al.  Could Polyphenols Help in the Control of Rheumatoid Arthritis? , 2019, Molecules.

[12]  C. Niemann,et al.  Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies , 2018, Drugs.

[13]  J. O’Shea,et al.  Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs , 2018, Journal of leukocyte biology.

[14]  Qingsong Liu,et al.  Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors. , 2018, Journal of medicinal chemistry.

[15]  J. Kirwan,et al.  Is There a Renaissance of Glucocorticoids in Rheumatoid Arthritis? , 2017, Clinical pharmacology and therapeutics.

[16]  Xiao-Ming Gao,et al.  A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis , 2017, Scientific Reports.

[17]  G. Firestein,et al.  Immunopathogenesis of Rheumatoid Arthritis. , 2017, Immunity.

[18]  M. Hegen,et al.  Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. , 2017, Journal of medicinal chemistry.

[19]  M. Davids,et al.  Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders , 2016, Cancer journal.

[20]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[21]  F. Salituro,et al.  Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. , 2015, Journal of medicinal chemistry.

[22]  R. Hendriks,et al.  BTK Signaling in B Cell Differentiation and Autoimmunity. , 2015, Current topics in microbiology and immunology.

[23]  S. Goodman.  Rheumatoid arthritis: Perioperative management of biologics and DMARDs. , 2015, Seminars in arthritis and rheumatism.

[24]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[25]  Leslie J Crofford,et al.  Use of NSAIDs in treating patients with arthritis , 2013, Arthritis Research & Therapy.

[26]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[27]  F. Uckun,et al.  Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft‐versus‐host disease (GVHD) in a murine allogeneic bone marrow transplantation model , 2004, British journal of haematology.